(Q38115205)

29 August 2017

title

Intermittent claudication: new targets for drug development (English)

1 reference

intermittent claudication

29 August 2017

main subject

1 reference

1 reference

Eric P Brass

1

1 reference

29 August 2017

publication date

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

73

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

999-1014

1 reference

Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society f

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The prevalence of peripheral arterial disease in a defined population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Peripheral arterial disease in the elderly: The Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Mortality over a period of 10 years in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Peripheral arterial disease of the lower extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Medical treatment of peripheral arterial disease and claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Assessment of disease impact in patients with intermittent claudication: discrepancy between health status and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy, and shift in muscle fiber type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Chronic changes in skeletal muscle histology and function in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Arterial dysfunction and functional performance in patients with peripheral artery disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Exercise training for claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Changes in myosin heavy chain mRNA and protein expression in human skeletal muscle with age and endurance exercise training

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The effect of exercise on haemodynamics in intermittent claudication: a systematic review of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Skeletal muscle adaptation in response to supervised exercise training for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Quality of life and functional status after revascularization or conservative treatment in patients with intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Functional status and walking ability after lower extremity bypass grafting or angioplasty for intermittent claudication: results from a prospective outcomes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Inhibition of endogenous TNF formation by pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Detraining: loss of training-induced physiological and performance adaptations. Part I: short term insufficient training stimulus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Growth factors for therapeutic angiogenesis in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Development of pluripotent stem cells for vascular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Regulation of human metabolism by hypoxia-inducible factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Cell therapy of peripheral arterial disease: from experimental findings to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Impaired muscle oxygen use at onset of exercise in peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Walking performance, oxygen uptake kinetics and resting muscle pyruvate dehydrogenase complex activity in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Chronically ischemic mouse skeletal muscle exhibits myopathy in association with mitochondrial dysfunction and oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Impaired skeletal muscle glucose uptake by [18F]fluorodeoxyglucose-positron emission tomography in patients with peripheral artery disease and intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

PPARs and the orchestration of metabolic fuel selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

RETRACTED: Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Carnitine: a nutritional, biosynthetic, and functional perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

European multicenter study on propionyl-L-carnitine in intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect of Propionyl-L-carnitine on a Background of Monitored Exercise in Patients With Claudication Secondary to Peripheral Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Pharmacokinetics of L-carnitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Turnover of carnitine by rat tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Production of reactive oxygen species by mitochondria: central role of complex III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Molecular mechanisms of superoxide production by the mitochondrial respiratory chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Vitamin C exhibits pro-oxidant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Antioxidants in peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Status of myocardial antioxidants in ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The biological roles of glutaredoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Moderate exercise is an antioxidant: upregulation of antioxidant genes by training.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Exercise training-induced alterations in skeletal muscle antioxidant capacity: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetyl cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Superficial femoral artery plaque, the ankle-brachial index, and leg symptoms in peripheral arterial disease: the walking and leg circulation study (WALCS) III

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The influence of atorvastatin on walking performance in peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Narrative review: statin-related myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Local control of skeletal muscle blood flow during exercise: influence of available oxygen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

L-arginine supplementation in peripheral arterial disease: no benefit and possible harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The DDAH-ADMA-NOS pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

DDAH: a target for vascular therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

A randomized trial of iloprost in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Skeletal muscle BOLD MRI: from underlying physiological concepts to its usefulness in clinical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Considerations in the development of drugs to treat sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Novel intriguing strategies attenuating to sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Controlling muscle mitochondrial content

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Testosterone supplementation for aging-associated sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Molecular mechanism of preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and mediator of ischemic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Stent thrombosis--risk assessment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effects of walking and strength training on resting and exercise cardiovascular responses in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0078-3

Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease

21 January 2018

1 reference

12 December 2020

Carnitine supplementation: effect on muscle carnitine and glycogen content during exercise

1 reference

12 December 2020

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions

1 reference

12 December 2020

Ischemic preconditioning specifically restores complexes I and II activities of the mitochondrial respiratory chain in ischemic skeletal muscle

1 reference

12 December 2020

Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease

1 reference

12 December 2020

Adaptations of skeletal muscle to endurance exercise and their metabolic consequences

1 reference

12 December 2020

L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study

1 reference

12 December 2020

A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.

1 reference

12 December 2020

Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study

1 reference

12 December 2020

Insulin stimulates L-carnitine accumulation in human skeletal muscle

1 reference

12 December 2020

Metabolic effects of propionate, hexanoate and propionylcarnitine in normoxia, ischaemia and reperfusion. Does an anaplerotic substrate protect the ischaemic myocardium?

1 reference

12 December 2020

Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease

1 reference

12 December 2020

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

1 reference

12 December 2020

Factors predicting walking intolerance in patients with peripheral arterial disease and intermittent claudication.

1 reference

12 December 2020

Pentoxifylline for intermittent claudication

1 reference

12 December 2020

Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of different treatments and consequences on walking performance

1 reference

12 December 2020

The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial

1 reference

12 December 2020

1 reference

12 December 2020

Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease

1 reference

12 December 2020

Effects of physical training in intermittent claudication

1 reference

12 December 2020

Restoring vascular nitric oxide formation by l-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease

1 reference

12 December 2020

Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication

1 reference

12 December 2020

Multiple‐Dose Pharmacokinetics and Bioequivalence L-Carnitine 330-mg Tablet versus 1-g Chewable Tablet versus Enteral Solution in Healthy Adult Male Volunteers

1 reference

12 December 2020

Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease

1 reference

12 December 2020

Propionyl-L-carnitine effects on postischemic recovery of heart function and substrate oxidation in the diabetic rat

1 reference

12 December 2020

Carnitine--metabolism and functions

1 reference

12 December 2020

Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects

1 reference

12 December 2020

Multiple skeletal muscle mitochondrial DNA deletions in patients with unilateral peripheral arterial disease

1 reference

12 December 2020

Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor

1 reference

12 December 2020

1 reference

12 December 2020

Experimental model of short-time exercise-induced preconditioning in POAD patients

1 reference

12 December 2020

Randomized controlled trial of antioxidants in intermittent claudication

1 reference

12 December 2020

Peripheral arterial disease affects kinematics during walking

1 reference

12 December 2020

Naftidrofuryl for intermittent claudication

1 reference

12 December 2020

Enzyme activities in skeletal muscles from patients with peripheral arterial insufficiency

1 reference

12 December 2020

Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus

1 reference

12 December 2020

Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar.

1 reference

12 December 2020

Restrictions in systemic and locomotor skeletal muscle perfusion, oxygen supply and VO2 during high-intensity whole-body exercise in humans

1 reference

12 December 2020

Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial

1 reference

12 December 2020

The fate of patients with critical leg ischemia

1 reference

12 December 2020

Exercise for intermittent claudication

1 reference

12 December 2020

Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC).

1 reference

12 December 2020

Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response

1 reference

12 December 2020

Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease

1 reference

12 December 2020

Mitochondrial defects and oxidative damage in patients with peripheral arterial disease

1 reference

12 December 2020

1 reference

12 December 2020

Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study

1 reference

12 December 2020

Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery

1 reference

12 December 2020

Vitamin E for intermittent claudication

1 reference

12 December 2020

Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease

1 reference

12 December 2020

Naftidrofuryl for intermittent claudication

1 reference

12 December 2020

Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease

1 reference

12 December 2020

Fish oil supplementation in patients with stable claudication

1 reference

12 December 2020

Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans

1 reference

12 December 2020

Muscle metabolism in patients with peripheral vascular disease investigated by 31P nuclear magnetic resonance spectroscopy

1 reference

12 December 2020

Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease

1 reference

12 December 2020

The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study

1 reference

12 December 2020

The pro-oxidant activity of high-dose vitamin E supplements in vivo

1 reference

12 December 2020

Sustained elevation of circulating vascular endothelial growth factor after percutaneous angioplasty for peripheral arterial diseases

1 reference

12 December 2020

Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle

1 reference

12 December 2020

Mechanisms for exercise training-induced increases in skeletal muscle blood flow capacity: differences with interval sprint training versus aerobic endurance training

1 reference

12 December 2020

Maximal strength training improves walking performance in peripheral arterial disease patients

1 reference

12 December 2020

A pilot study of ranolazine in patients with intermittent claudication

1 reference

12 December 2020

Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury

1 reference

12 December 2020

10.1007/S40265-013-0078-3

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1044433517

0 references

1 reference